
Annual report 2025
added 03-06-2026
IRadimed Corporation Revenue 2011-2026 | IRMD
Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.
Traditionally defined as follows:Revenue = Price * Quantity of productsRevenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.[1]
This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.
Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.
Annual Revenue IRadimed Corporation
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 83.8 M | 73.2 M | 65.6 M | 53.3 M | 41.8 M | 31.7 M | 38.5 M | 30.4 M | 23.1 M | 32.5 M | 31.6 M | 15.7 M | 11.3 M | 7.69 M | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 83.8 M | 7.69 M | 38.6 M |
Quarterly Revenue IRadimed Corporation
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 21.2 M | 20.4 M | 19.5 M | - | 18.3 M | 17.9 M | 17.6 M | - | 16.5 M | 16.1 M | 15.5 M | - | 13.4 M | 12.7 M | 12.3 M | - | 10.9 M | 9.81 M | 9.22 M | - | 7.7 M | 6.79 M | 8.68 M | - | 9.96 M | 9.23 M | 8.44 M | - | 7.61 M | 7.38 M | 7.11 M | - | 5.69 M | 5.52 M | 5.16 M | - | 7.67 M | 9.87 M | 8.96 M | - | 8.19 M | 7.61 M | 6.99 M | - | 3.81 M | 4.7 M | 3.56 M | - | 2.48 M | 2.78 M | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 21.2 M | 2.48 M | 10.2 M |
References
- Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).
Revenue of other stocks in the Medical devices industry
| Issuer | Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
GenMark Diagnostics, Inc.
GNMK
|
172 M | - | - | $ 1.77 B | ||
|
Axonics Modulation Technologies
AXNX
|
274 M | - | - | $ 3.31 B | ||
|
Helius Medical Technologies
HSDT
|
644 K | $ 1.99 | -7.87 % | $ 1.21 M | ||
|
Aziyo Biologics
AZYO
|
12.3 M | - | 1.37 % | $ 20.5 M | ||
|
Acutus Medical
AFIB
|
7.16 M | - | -26.83 % | $ 2.62 M | ||
|
Integra LifeSciences Holdings Corporation
IART
|
1.61 B | $ 9.37 | -1.94 % | $ 722 M | ||
|
BioSig Technologies
BSGM
|
40 K | - | 37.08 % | $ 85.7 M | ||
|
Inogen
INGN
|
349 M | $ 6.51 | 1.32 % | $ 173 M | ||
|
Allied Healthcare Products
AHPI
|
6.02 M | - | 3.58 % | $ 2.21 M | ||
|
Obalon Therapeutics, Inc.
OBLN
|
1.59 M | - | -5.86 % | $ 30.6 M | ||
|
IRIDEX Corporation
IRIX
|
51.9 M | $ 1.32 | -0.38 % | $ 21.3 M | ||
|
LENSAR
LNSR
|
53.5 M | $ 5.55 | -0.63 % | $ 63.9 M | ||
|
Conformis
CFMS
|
62 M | - | - | $ 16.4 M | ||
|
Delcath Systems
DCTH
|
85.2 M | $ 9.08 | -1.3 % | $ 325 M | ||
|
Medtronic PLC
MDT
|
33.5 B | $ 87.7 | -0.2 % | $ 113 B | ||
|
Dynatronics Corporation
DYNT
|
27.4 M | - | 14.99 % | $ 929 K | ||
|
Cardiovascular Systems
CSII
|
236 M | - | 0.15 % | $ 844 M | ||
|
Second Sight Medical Products
EYES
|
1 K | - | -0.97 % | $ 54.4 M | ||
|
Apollo Endosurgery
APEN
|
76.9 M | - | - | $ 475 M | ||
|
Avinger
AVGR
|
7.65 M | - | -20.74 % | $ 369 K | ||
|
Orthofix Medical
OFIX
|
822 M | $ 11.73 | -1.68 % | $ 465 M | ||
|
CryoLife, Inc.
CRY
|
253 M | - | -4.14 % | $ 702 M | ||
|
Outset Medical
OM
|
119 M | $ 3.48 | -1.56 % | $ 52.9 K | ||
|
CONMED Corporation
CNMD
|
1.37 B | $ 36.19 | -2.4 % | $ 1.12 B | ||
|
Insulet Corporation
PODD
|
2.71 B | $ 219.0 | 1.39 % | $ 15.4 B | ||
|
Hancock Jaffe Laboratories, Inc.
HJLI
|
4.25 K | - | -1.98 % | $ 98.3 M | ||
|
Itamar Medical Ltd.
ITMR
|
41 M | - | 0.03 % | $ 1.58 B | ||
|
Quanterix Corporation
QTRX
|
139 M | $ 3.95 | -0.25 % | $ 168 M | ||
|
Electromed
ELMD
|
64 M | $ 24.52 | -0.57 % | $ 207 M | ||
|
Misonix, Inc.
MSON
|
62.5 M | - | - | $ 462 M | ||
|
Neovasc
NVCN
|
2.55 M | - | - | $ 111 M | ||
|
Intersect ENT, Inc.
XENT
|
80.6 M | - | - | $ 955 M | ||
|
Cytosorbents Corporation
CTSO
|
35.6 M | $ 0.62 | -8.01 % | $ 33.7 M | ||
|
Aethlon Medical
AEMD
|
574 K | $ 2.33 | 0.43 % | $ 3.64 M | ||
|
Sintx Technologies
SINT
|
1.02 M | $ 2.42 | -5.47 % | $ 6.71 M | ||
|
BIOLASE
BIOL
|
49.2 M | - | -13.19 % | $ 166 K | ||
|
LivaNova PLC
LIVN
|
1.39 B | $ 63.79 | 0.77 % | $ 3.48 B | ||
|
InspireMD
NSPR
|
8.98 M | $ 1.73 | -1.14 % | $ 111 M | ||
|
Sensus Healthcare
SRTS
|
27.5 M | $ 4.05 | -4.03 % | $ 66.1 M | ||
|
AdaptHealth Corp.
AHCO
|
3.24 B | $ 11.45 | 0.48 % | $ 1.55 B | ||
|
Penumbra
PEN
|
1.4 B | $ 336.8 | 0.16 % | $ 13.1 B | ||
|
Stryker Corporation
SYK
|
7.17 B | $ 332.15 | 1.37 % | $ 127 B | ||
|
MiMedx Group
MDXG
|
419 M | $ 3.96 | -3.54 % | $ 585 M | ||
|
TELA Bio
TELA
|
80.3 M | $ 0.75 | 8.07 % | $ 35.2 M | ||
|
Invacare Corporation
IVC
|
181 M | - | - | $ 24.7 M | ||
|
Myomo
MYO
|
40.9 M | $ 0.68 | -2.24 % | $ 28.5 M |